专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5532266A Acrylacetamides 失效
标题翻译：丙烯酰胺
公开(公告)号：US5532266A
公开(公告)日：1996-07-02
申请号：US453811
申请日：1995-05-30
申请人： Rudolf Gottschlich , Karl-August Ackermann , Helmut Prucher , Christoph Seyfried , Hartmut Greiner , Gerd Bartoszyk , Frank Mauler , Manfred Stohrer , Andrew Barber
发明人： Rudolf Gottschlich , Karl-August Ackermann , Helmut Prucher , Christoph Seyfried , Hartmut Greiner , Gerd Bartoszyk , Frank Mauler , Manfred Stohrer , Andrew Barber
IPC分类号： A61K31/435 , A61K31/165 , A61K31/17 , A61K31/35 , A61K31/40 , A61K31/4025 , A61K31/47 , A61K31/472 , A61K31/495 , A61K31/535 , A61P7/10 , A61P11/08 , A61P11/14 , A61P25/04 , A61P25/08 , A61P25/28 , A61P29/00 , A61P43/00 , C07C233/00 , C07C233/05 , C07C233/08 , C07D207/08 , C07D207/09 , C07D207/12 , C07D215/00 , C07D217/06 , C07D217/14 , C07D295/12 , C07D295/135 , C07D311/84 , C07D401/06 , C07D403/06 , C07D405/06 , C07D405/12 , C07D409/06 , C07D413/06 , C07D207/36 , C07D207/325
CPC分类号： C07D405/06 , C07D207/09 , C07D207/12 , C07D217/14 , C07D311/84 , C07D405/12
摘要： Novel arylacetamides of the formula I ##STR1## in which Q is R.sup.4 --CH(CH.sub.2 Z)--NA--, ##STR2## R.sup.1 is Ar, cycloalkyl with 3-7 C atoms or C.sub.4 -C.sub.8 -cycloalkyl-C.sub.1 -C.sub.7 -alkyl,R.sup.2 is Ar,R.sup.3 is H, OH, OA or A,R.sup.4 is A or phenyl which can optionally be substituted once or twice by F, Cl, Br, I, OH, OA, CF.sub.3, NO.sub.2, NH.sub.2, NHA, NHCOA, NHSO.sub.2 A or NA.sub.2,R.sup.5 and R.sup.6 are each, independently of one another, H, F, Cl, Br, I, OH, OA, CF.sub.3, NH.sub.2, NHA, NA.sub.2, NHCOA, NHCONH.sub.2, NO.sub.2 or taken together are methylenedioxy,A is alkyl with 1-7 C atoms, and physiologically acceptable salts thereof.
摘要翻译：其中Q为R4-CH（CH2Z）-NA-，R1为Ar，具有3-7个C原子的环烷基或C 4 -C 8 - 环烷基-C 1 -C 4烷基的新的芳基乙酰胺， C7-烷基，R2是Ar，R3是H，OH，OA或A，R4是A或可以被F，Cl，Br，I，OH，OA，CF3，NO2，NH2等任意取代一次或两次的苯基， NHA，NHCOA，NHSO2A或NA2，R5和R6各自独立地为H，F，Cl，Br，I，OH，OA，CF3，NH2，NHA，NA2，NHCOA，NHCONH2，亚甲二氧基，A是具有1-7个C原子的烷基，以及其生理上可接受的盐。

2. 发明授权

US5472961A Acetamides 失效
标题翻译：乙酰胺
公开(公告)号：US5472961A
公开(公告)日：1995-12-05
申请号：US397758
申请日：1995-03-02
申请人： Rudolf Gottschlich , Karl-August Ackermann , Christoph Seyfried , Andrew Barber , Gerd Bartoszyk , Hartmut Greiner
发明人： Rudolf Gottschlich , Karl-August Ackermann , Christoph Seyfried , Andrew Barber , Gerd Bartoszyk , Hartmut Greiner
IPC分类号： C07D413/06 , A61K31/42 , A61K31/47 , A61P9/10 , A61P25/00 , A61P25/04 , A61P43/00 , C07D235/26 , C07D263/58 , C07D265/36 , C07D265/38 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D413/12 , C07D413/14
CPC分类号： C07D263/58 , C07D235/26 , C07D265/36 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12 , C07D413/14
摘要： Novel acetamides of the formula I ##STR1## in which Q, R, X and Y have the meanings defined herein, have analgesic and neuroprotective properties and bind with high affinity to kappa receptors.
摘要翻译：其中Q，R，X和Y具有本文定义的含义的式I“I”的新型乙酰胺具有止痛和神经保护性质，并以高亲和力结合κ受体。

3. 发明授权

US5977161A Kappa-opiate agonists effective in the treatment of postoperative ileus 失效
标题翻译：卡帕阿片激动剂有效治疗术后肠梗阻
公开(公告)号：US5977161A
公开(公告)日：1999-11-02
申请号：US27228
申请日：1998-02-20
申请人： Andrew Barber , Christoph Seyfried , Gerd Bartoszyk , Rudolf Gottschlich
发明人： Andrew Barber , Christoph Seyfried , Gerd Bartoszyk , Rudolf Gottschlich
IPC分类号： C07D207/08 , A61K31/135 , A61K31/165 , A61K31/40 , A61K31/4015 , A61K31/4025 , A61P1/00 , A61P1/04 , A61P29/00 , A61P43/00 , C07D207/12
CPC分类号： A61K31/4025
摘要： Disclosed herein are pharmaceutical preparations which are suitable for the treatment of postoperative ileus and contain at least one compound of the formula I ##STR1## in which R.sup.1 is Ar, cycloalkyl having 3-7 C atoms or cycloalkylalkyl having 4-8 C atoms,R.sup.2 is Ar, orR.sub.1 and R.sup.2 together are ##STR2## R.sup.3 is H, OH, OA or A, R.sup.4 is A or phenyl which can optionally be mono- or disubstituted by Hal, OH, OA, CF.sub.3, NO.sub.2, NH.sub.2, NHA, NHCOA, NHSO.sub.2 A and/or NA.sub.2,R.sup.5 is OH, CH.sub.2 OH,R.sup.6 and R.sup.7 in each case independently of one another are H, Hal, OH, OA, CF.sub.3, NH.sub.2, NHA, NA.sub.2, NHCOA, NHCONH.sub.2, NO.sub.2 or methylenedioxy, with the oxy groups bonded to adjacent carbons on the ring,A is alkyl having 1-7 C atoms,Ar is a mono- or bicyclic aromatic radical which can optionally contain an N, O or S atom in the ring and can be mono-, di- or trisubstituted by A, Hal, OH, OA, CF.sub.3, NH.sub.2, NHA, NA.sub.2, NHCOA and/or NHCONH.sub.2,D is CH.sub.2, O, S, NH, NA, --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--, --CH.sub.2 NH--, --CH.sub.2 --NA-- or a bondandHal is F, Cl, Br or I.
摘要翻译：本文公开了适用于治疗术后肠梗阻并含有至少一种其中R 1为Ar的式I化合物或具有3-7个C原子的环烷基或具有4-8个C原子的环烷基烷基，R2为Ar，或R 1和R 2一起为R 3为H，OH，OA或A，R 4为A或可任选被Hal，OH，OA，CF 3，NO 2，NH 2，NHA，NHCOA，NHSO 2 A单取代或二取代的苯基和/或 NA2，R5分别为H，Hal，OH，OA，CF3，NH2，NHA，NA2，NHCOA，NHCONH2，NO2或亚甲二氧基的OH，CH2OH，R6和R7彼此独立地键合， A是具有1-7个C原子的烷基，Ar是可以在环中任选含有N，O或S原子的单环或双环芳族基团，并且可以被A，，Hal，OH，OA，CF 3，NH 2，NHA，NA 2，NHCOA和/或NHCONH 2，D是CH 2，O，S，NH，NA，-CH 2 -CH 2 - ， - CH = CH-， - CH 2 NH-， CH2-NA-或键，Hal为F，Cl，Br或I.

4. 发明授权

US5776972A Kappa-opiate agonists for inflammatory bowel disorders 失效
标题翻译：卡帕酸激动剂用于炎症性肠病
公开(公告)号：US5776972A
公开(公告)日：1998-07-07
申请号：US671502
申请日：1996-06-27
申请人： Andrew Barber , Christoph Seyfried , Gerd Bartoszyk , Rudolf Gottschlich
发明人： Andrew Barber , Christoph Seyfried , Gerd Bartoszyk , Rudolf Gottschlich
IPC分类号： C07D207/08 , A61K31/135 , A61K31/165 , A61K31/40 , A61K31/4015 , A61K31/4025 , A61P1/00 , A61P1/04 , A61P29/00 , A61P43/00 , C07D207/12
CPC分类号： A61K31/4025
摘要： Pharmaceutical preparations which are suitable for the treatment of inflammatory bowel disorders and contain at least one compound of the formula I ##STR1## in which R.sup.1 is Ar, cycloalkyl having 3-7 C atoms or cycloalkylalkyl having 4-8 C atoms, R.sup.2 is Ar, or R.sup.1 and R.sup.2 together are ##STR2## R.sup.3 is H, OH, OA or A, R.sup.4 is A or phenyl which can optionally be mono- or disubstituted by Hal, OH, OA, CF.sub.3, NO.sub.2, NH.sub.2, NHA, NHCOA, NHSO.sub.2 A and/or NA.sub.2, R.sup.5 is OH, CH.sub.2 OH, R.sup.6 and R.sup.7 in each case independently of one another are H, Hal, OH, OA, CF.sub.3, NH.sub.2, NHA, NA.sub.2, NHCOA, NHCONH.sub.2, NO.sub.2 or methylenedioxy, with the oxy groups bonded to adjacent carbons on the ring, A is alkyl having 1-7 C atoms, Ar is a mono- or bicyclic aromatic radical which can optionally contain an N, O or S atom in the ring and can be mono-, di- or trisubstituted by A, Hal, OH, OA, CF.sub.3, NH.sub.2, NHA, NA.sub.2, NHCOA and/or NHCONH.sub.2,D is CH.sub.2, O, S, NH, NA, --CH.sub.2 --CH.sub.2 --,--CH.dbd.CH--,--CH.sub.2 --NH--,--CH.sub.2 --NA-- or a bond and Hal is F, Cl, Br or I; and/or physiologically acceptable salts and/or one of its glycosylated derivatives , and at least one physiologically acceptable excipient or auxiliary.
摘要翻译：适用于治疗炎症性肠病并含有至少一种式I g 3-7 C原子的化合物或具有4-8个C原子的环烷基烷基的药物制剂，R 2为Ar或R 1和R 2一起为“ R3是H，OH，OA或A，R4是A或可以被Hal，OH，OA，CF3，NO2，NH2，NHA，NHCOA，NHSO2A和/或NA2单取代或二取代的苯基，R5是OH， CH 2 OH，R 6和R 7各自独立地为H，Hal，OH，OA，CF 3，NH 2，NHA，NA 2，NHCOA，NHCONH 2，NO 2或亚甲二氧基，氧基与环上的相邻碳键合，A 是具有1-7个C原子的烷基，Ar是单环或双环芳族基团，其可以任选地在环中含有N，O或S原子，并且可以被A，Hal，OH，OA单取代，二取代或三取代，CF 3，NH 2，NHA，NA 2，NHCOA和/或NHCONH 2，D是CH 2，O，S，NH，NA，-CH 2 -CH 2 - ， - CH = CH - ， - CH 2 -NH-， - CH 2 - 或键，Hal为F，Cl，Br或I; 和/或生理上可接受的盐和/或其糖基化衍生物之一，和至少一种生理上可接受的赋形剂或辅助剂。

5. 发明授权

US06333339B1 3-Benzylpiperidine 失效
标题翻译： 3-苄基哌啶
公开(公告)号：US06333339B1
公开(公告)日：2001-12-25
申请号：US09445587
申请日：2000-04-17
申请人： Henning Boettcher , Helmut Pruecher , Hartmut Greiner , Christoph Seyfried , Andrew Barber , Joseph Maria Martinez
发明人： Henning Boettcher , Helmut Pruecher , Hartmut Greiner , Christoph Seyfried , Andrew Barber , Joseph Maria Martinez
IPC分类号： A61K31445
CPC分类号： C07D401/06
摘要： The invention relates to piperidine derivatives of the formula I in which R1, R2, m and k have the meanings indicated in claim 1, and their salts, novel intermediates and processes for the preparation of the compounds according to the invention. The compounds of the formula I are potent a receptor ligands and show 5-HT reuptake-inhibiting actions and can be used for the production of medicaments, for example for the treatment of disorders of the central nervous system, of strokes, brain or bone marrow traumata or of ischaemic states.
摘要翻译：本发明涉及式Iin的哌啶衍生物，其中R1，R2，m和k具有权利要求1所示的含义，以及它们的盐，新的中间体和制备本发明化合物的方法。我是有效的受体配体并显示出5-HT再摄取抑制作用，可以用于制备药物，例如用于治疗中枢神经系统疾病，脑卒中，脑或骨髓创伤或缺血状态。

6. 发明授权

US06548516B1 1-(3-heteroarylpropyl- or -prop-2-enyl)-4-benzylpiperidines used as NMDA receptor antagonists 失效
标题翻译：用作NMDA受体拮抗剂的1-（3-杂芳基丙基 - 或 - 丙-2-烯基）-4-苄基哌啶
公开(公告)号：US06548516B1
公开(公告)日：2003-04-15
申请号：US09646185
申请日：2000-09-14
申请人： Helmut Prücher , Joachim Leibrock , Andrew Barber , Gerd Bartoszyk
发明人： Helmut Prücher , Joachim Leibrock , Andrew Barber , Gerd Bartoszyk
IPC分类号： A61K31445
CPC分类号： C07D401/06 , C07D413/06 , C07D417/06
摘要： Piperidine derivatives of the formula I and their physiologically acceptable salts in which X, Y, Z, R1, R2, R3 and R4 are as defined in claim 1 can be as excitatory amino acid antagonists for combating neurodegenerative disorders including cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease and Huntington's disease, cerebral ischaemias, infarcts and psychosis.
摘要翻译：式I的哌啶衍生物及其生理上可接受的盐，其中X，Y，Z，R 1，R 2，R 3和R 4如权利要求1中所定义，可以作为用于对抗神经变性障碍的兴奋性氨基酸拮抗剂，包括脑血管疾病，癫痫，精神分裂症，阿尔茨海默病，帕金森病和亨廷顿病，脑缺血，梗塞和精神病。

7. 发明申请

US20050176746A1 Use of compounds that are effective as selective opiate receptor modulators 审中-公开
标题翻译：使用有效作为选择性鸦片剂受体调节剂的化合物
公开(公告)号：US20050176746A1
公开(公告)日：2005-08-11
申请号：US10514887
申请日：2003-04-28
申请人： Frank Weber , Jutta Jacob , Andrew Barber , Rudolf Gottschlich
发明人： Frank Weber , Jutta Jacob , Andrew Barber , Rudolf Gottschlich
IPC分类号： A61K45/00 , A61K31/135 , A61K31/137 , A61K31/337 , A61K31/40 , A61K31/439 , A61K31/445 , A61K31/451 , A61K31/485 , A61P1/00 , A61P3/04 , A61P25/00 , A61P35/00 , A61P43/00
CPC分类号： A61K31/40 , A61K31/135 , A61K31/445 , A61K31/485
摘要： The instant invention relates to the use of compounds that are effective as selective opiate receptor modulators for the manufacture of pharmaceuticals for the diagnosis and/or the treatment of disorders, said disorders being selected from eating disorders and digestive disorders, especially psychogenic eating disorders, for the manufacture of a pharmaceutical effective for modulating, the gastrointestinal tonus, and to pharmaceutical composition, comprising one or more of said modulator compounds and one or more compounds that are effective as appetite depressant.
摘要翻译：本发明涉及使用有效作为选择性鸦片剂受体调节剂用于制备用于诊断和/或治疗疾病的药物的所述疾病，所述疾病选自进食障碍和消化系统疾病，特别是心理性进食障碍，用于制造有效调节胃肠炎的药物和药物组合物，其包含一种或多种所述调节剂化合物和一种或多种作为食欲抑制剂有效的化合物。

8. 发明授权

US4950648A Analgesic 失效
标题翻译：止痛药
公开(公告)号：US4950648A
公开(公告)日：1990-08-21
申请号：US271463
申请日：1988-11-15
申请人： Peter Raddatz , Wolf-Dietrich Weber , Andrew Barber , Hans-Peter Wolf , Christoph Seyfried
发明人： Peter Raddatz , Wolf-Dietrich Weber , Andrew Barber , Hans-Peter Wolf , Christoph Seyfried
IPC分类号： A61K31/505 , A61P25/04 , C07D471/04 , C07D487/04
CPC分类号： A61K31/505
摘要： New analgesic compositions containing a compound of the formula I ##STR1## wherein .dbd.A--B.dbd. is .dbd.CH--CH.dbd. or --N--CR.sup.2 .dbd.,Alk is an alkylene group having 2-4 C atoms,R.sup.1 is H, dialkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, carbamoylalkyl, N-alkylcarbamoylalkyl or N,N-dialkylcarbamoylalkyl,Y is CH or N,Z is a bond or --CO--,Ar is a phenyl, thienyl or pyridyl group which is unsubstituted or substituted one or more times by alkyl, alkoxy, F, Cl, Br, I and/or CF.sub.3, andR.sup.2 is H, alkyl, alkoxy or alkylthio,in which the alkyl, alkoxy and alkylthio groups each contain 1-4 C atoms, and/or one of its physiologically acceptable salts.
摘要翻译：其中= AB = = CH-CH =或-N-CR2 =，Alk是具有2-4个C原子的亚烷基，R 1是H，二烷基氨基烷基，羧基烷基，烷氧基羰基烷基，氨基甲酰基烷基，N-烷基氨基甲酰基烷基或N，N-二烷基氨基甲酰基烷基，Y是CH或N，Z是一个键或-CO-，Ar是未被取代或被烷基取代一次或多次的苯基，噻吩基或吡啶基，烷氧基，F，Cl，Br，I和/或CF 3，并且R 2是H，烷基，烷氧基或烷硫基，其中烷基，烷氧基和烷硫基各自含有1-4个C原子，和/或其生理上可接受的一种盐。

9. 发明授权

US06667923B1 RAM data array configured to provide data-independent, write cycle coherent current drain 有权
标题翻译： RAM数据阵列配置为提供数据无关，写周期相干电流消耗
公开(公告)号：US06667923B1
公开(公告)日：2003-12-23
申请号：US10205862
申请日：2002-07-26
申请人： Gregory Jay DelMain , John Gord , Lawrence J. Karr , Paul De Rocco , Glenn A. DeMichele , Douglas Kerns , Andrew Barber
发明人： Gregory Jay DelMain , John Gord , Lawrence J. Karr , Paul De Rocco , Glenn A. DeMichele , Douglas Kerns , Andrew Barber
IPC分类号： G11C702
CPC分类号： G11C7/1036
摘要： An apparatus and method for forming a RAM data memory that generates predictable noise/interference components that are coherent with each write cycle and essentially independent of the data content of the RAM data memory. The RAM data memory is comprised of a plurality of cells, each representing a data bit, which are selectively addressable as memory bytes formed of multiple bits. Each cell is formed of two sets of cross-coupled transistors. By causing each set of cross-coupled transistors to be set to a common voltage level at the beginning of a write cycle before setting one set of transistors to a low level and the one set of transistors to be set to a high level (thus representing a desired data bit value), the associated noise/interference components of the power drain are data independent. Furthermore, the data-independent noise occurs at frequencies at or above the write cycle rate.
摘要翻译：一种用于形成RAM数据存储器的装置和方法，所述RAM数据存储器产生与每个写周期相干并且基本上独立于RAM数据存储器的数据内容的可预测的噪声/干扰分量。 RAM数据存储器由多个单元组成，每个单元表示数据位，其可选择地可寻址为由多位形成的存储器字节。每个单元由两组交叉耦合晶体管组成。通过在将一组晶体管设置为低电平并且将一组晶体管设置为高电平（从而代表一个晶体管的一组）之前，将每组交叉耦合晶体管设置为写周期开始时的公共电压电平期望的数据位值），功率相关的噪声/干扰分量是数据无关的。而且，数据无关的噪声出现在等于或高于写周期速率的频率。

10. 发明授权

US06472991B1 Multichannel communication protocol configured to extend the battery life of an implantable device 有权
标题翻译：多通道通信协议被配置为延长可植入设备的电池寿命
公开(公告)号：US06472991B1
公开(公告)日：2002-10-29
申请号：US09882603
申请日：2001-06-15
申请人： Joseph H. Schulman , John C. Gord , Paul D. DeRocco , Lawrence J. Karr , Dan Folkman , Andrew Barber
发明人： Joseph H. Schulman , John C. Gord , Paul D. DeRocco , Lawrence J. Karr , Dan Folkman , Andrew Barber
IPC分类号： G08B2100
CPC分类号： A61N1/37276 , A61N1/3787 , H04W52/0219 , Y02D70/26
摘要： A communication protocol that is configured to extend the battery life of devices that monitor and/or affect body parameters and is particularly useful in a system comprised of a system control unit (SCU) and one or more implanted devices. Each such implanted device is configured to be monitored and/or controlled by the SCU via a wireless communication channel. The time between battery rechargings is determined by the battery capacity and the device's power consumption. Accordingly, the present invention reduces their average power consumption by reducing the usage duty cycle of their power consuming transmit and receive modes used to communicate with the SCU. By dedicating addressable time slots to each of the implantable devices in the system and limiting their use of receive and transmit modes to time periods proximate to these time slots, the average power consumption is accordingly reduced.
摘要翻译：配置为延长监视和/或影响身体参数的设备的电池寿命的通信协议，并且在由系统控制单元（SCU）和一个或多个植入设备组成的系统中特别有用。每个这样的植入装置被配置为经由无线通信信道由SCU监视和/或控制。电池充电之间的时间取决于电池容量和设备的功耗。因此，本发明通过减少用于与SCU通信的功耗发送和接收模式的使用占空比来降低它们的平均功耗。通过将可寻址时隙专用于系统中的每个可植入设备，并将接收和发射模式的使用限制在接近这些时隙的时间周期内，因此相应地降低了平均功耗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式